Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2.
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2.
复制标题
DOI:
10.3791/63127
复制
发表时间:
2021-11-05
期刊:
影响因子:
--
通讯作者:
Martínez-Sobrido L
中科院分区:
文献类型:
--
作者:
Morales Vasquez D;Chiem K;Silvas J;Park JG;Ye C;Martínez-Sobrido L
The coronavirus disease 2019 (COVID-19) pandemic has been caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, SARS-CoV-2 has been responsible for over 242 million infections and more than 4.9 million deaths worldwide. Similar to other viruses, studying SARS-CoV-2 requires the use of experimental methods to detect the presence of virus in infected cells and/or in animal models. To overcome this limitation, we generated replication-competent recombinant (r)SARS-CoV-2 that expresses bioluminescent (nanoluciferase, Nluc) or fluorescent (Venus) proteins. These reporter-expressing rSARS-CoV-2 allow tracking viral infections in vitro and in vivo based on the expression of Nluc and Venus reporter genes. Here the study describes the use of rSARS-CoV-2/Nluc and rSARS-CoV-2/Venus to detect and track SARS-CoV-2 infection in the previously described K18 human angiotensin-converting enzyme 2 (hACE2) transgenic mouse model of infection using in vivo imaging systems (IVIS). This rSARS-CoV-2/Nluc and rSARS-CoV-2/Venus show rSARS-CoV-2/WT-like pathogenicity and viral replication in vivo. Importantly, Nluc and Venus expression allow us to directly track viral infections in vivo and ex vivo, in infected mice. These rSARS-CoV-2/Nluc and rSARS-CoV-2/Venus represent an excellent option to study the biology of SARS-CoV-2 in vivo, to understand viral infection and associated COVID-19 disease, and to identify effective prophylactic and/or therapeutic treatments to combat SARS-CoV-2 infection.
登录
查看更多内容
DOI:
10.1056/nejmoa2034577
发表时间:
2020-12-31
期刊:
The New England journal of medicine
影响因子:
--
作者:
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者:
C4591001 Clinical Trial Group
DOI:
10.1056/nejmoa2102685
发表时间:
2021-10-07
期刊:
The New England journal of medicine
影响因子:
--
作者:
Dougan M;Nirula A;Azizad M;Mocherla B;Gottlieb RL;Chen P;Hebert C;Perry R;Boscia J;Heller B;Morris J;Crystal C;Igbinadolor A;Huhn G;Cardona J;Shawa I;Kumar P;Adams AC;Van Naarden J;Custer KL;Durante M;Oakley G;Schade AE;Holzer TR;Ebert PJ;Higgs RE;Kallewaard NL;Sabo J;Patel DR;Dabora MC;Klekotka P;Shen L;Skovronsky DM;BLAZE-1 Investigators
通讯作者:
BLAZE-1 Investigators
DOI:
10.7759/cureus.15280
发表时间:
2021-05-27
期刊:
Cureus
影响因子:
--
作者:
Phan AT;Gukasyan J;Arabian S;Wang S;Neeki MM
通讯作者:
Neeki MM
影响因子:
7.6
作者:
Li, Xiaodan;Zhang, Hongqing;Zhang, Bo
通讯作者:
Zhang, Bo
DOI:
10.1016/j.jbc.2021.100847
发表时间:
2021-07
期刊:
The Journal of biological chemistry
影响因子:
--
作者:
Evans JP;Liu SL
通讯作者:
Liu SL